LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited is expanding the reach of their innovative erectile dysfunction treatment, SPONTAN, with a second Australian men’s health expert now prescribing it under the TGA’s Special Access Scheme. SPONTAN is gaining attention for its rapid onset and improved side effect profile compared to traditional oral ED medications. This strategic engagement with healthcare providers is poised to increase SPONTAN’s market presence and improve patient outcomes in men’s health.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
